State at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's state.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's state?
- BioCryst Pharmaceuticals (BCRX) reported state of -$46K in Q4 2025.
- How has BioCryst Pharmaceuticals's state changed year-over-year?
- BioCryst Pharmaceuticals's state decreased by 332.9% year-over-year, from $19.75K to -$46K.
- What is the long-term trend for BioCryst Pharmaceuticals's state?
- Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's state has grown at a 23.8% compound annual growth rate (CAGR), from -$120K to -$184K.
- What does state mean?
- Represents the portion of state and local income tax expense or benefit that is deferred to future periods due to temporary differences between the financial reporting and tax bases of assets and liabilities. This metric helps investors understand the impact of state-level tax accounting timing differences on the company's future cash tax obligations.